cordycepin has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, XQ; He, Y; Hong, YX; Huang, WM; Qiu, L; Sun, Y; Tang, PC; Yu, BC; Zhang, X; Zhang, XL; Zhang, XY | 1 |
| Cheng, C; Zhu, X | 1 |
2 other study(ies) available for cordycepin and Parkinsonian Disorders
| Article | Year |
|---|---|
Anti-inflammatory and neuroprotective effects of natural cordycepin in rotenone-induced PD models through inhibiting Drp1-mediated mitochondrial fission.
Topics: Animals; Anti-Inflammatory Agents; Deoxyadenosines; Dose-Response Relationship, Drug; Dynamins; Insecticides; Male; Mitochondrial Dynamics; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotenone | 2021 |
Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Line, Tumor; Deoxyadenosines; Lipopolysaccharides; Male; Microglia; Motor Activity; Neuroprotective Agents; NF-kappa B; Oxidative Stress; Parkinsonian Disorders; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptors | 2019 |